Work

Subacute cutaneous lupus erythematosus-like drug eruption after durvalumab treatment for squamous cell carcinoma

Year: 2025

Type: article

Abstract: Cutaneous immune-related adverse events are increasingly reported with the expanding use of immune checkpoint inhibitors to treat various cancers. A subacute cutaneous lupus erythematosus-like drug eruption was observed in a patient with durvalumab infusion, with increasing severity after each dose. The eruption improved with cessation of durvalumab, hydroxychloroquine therapy, and sun protection.

Source: Dermatology Online Journal

DOI: 10.25251/10agjt29

Authors: Dasha Giger, Danielle Y. Del Mundo, Nidhi Avashia-Khemka

Institutions: Morehouse School of Medicine, Indiana University School of Medicine

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $300